TRT 'cycle review' videos: what gym TikTok gets wrong

What did @coach.neek actually say?

The creator argues that anabolic steroid users who plan to cycle again should drop to a TRT dose between blasts rather than stopping completely and using SERMs like clomid, tamoxifen, or raloxifene. He claims SERMs are "inherently toxic" and cause deep vein thrombosis through arterial damage. He also sets 200mg of testosterone per week as the upper ceiling for what he calls a healthy TRT dose, and says the timing between blasts should be driven by bloodwork, not fixed weeks-off calendars.

There's a lot packed into this video, some of it reasonable, some of it medically garbled, and one claim about SERMs and DVT that is genuinely wrong in a way that could mislead people into making worse decisions about their cardiovascular health.

Does the science back this up?

Partially. The blast-and-cruise model is real, and bloodwork-guided cycling is objectively more rational than arbitrary time-on-time-off rules. But the SERM-DVT mechanism he describes is not supported by the evidence, and his framing of SERMs as uniformly dangerous misrepresents a more complicated picture.

On the blast-and-cruise side: there's no clean RCT data comparing outcomes between blast-and-cruise versus full PCT-based cessation in recreational users, because this research is almost impossible to conduct ethically. What we do have are observational data showing that supraphysiologic testosterone use causes significant cardiovascular strain, including left ventricular hypertrophy and reduced ejection fraction, effects documented by Baggish et al. (2017, Circulation) in long-term AAS users. The idea that crashing hormones abruptly adds stress is biologically plausible, even if the comparative harm data are thin.

On SERMs and DVT: tamoxifen does carry a real venous thromboembolism risk, documented in breast cancer trials. The NSABP P-1 trial (Fisher et al., 1998, JNCI) showed roughly a 2.5x increased DVT risk versus placebo. But the mechanism is not arterial lacerations. That description is anatomically incoherent. The mechanism is changes in clotting factor expression and reduced protein S levels, not physical cuts in arteries.

What did they get wrong (or right)?

They got the SERM risk direction right but the mechanism badly wrong, and that matters. Describing DVT as resulting from "small lacerations" in arteries is not a simplification. It is incorrect. DVT occurs in veins, not arteries, and the pathophysiology involves Virchow's triad: hypercoagulability, venous stasis, and endothelial injury at the molecular level, not physical cuts. Telling people SERMs cause arterial gashes could lead someone to dismiss the real warning, or to trust the rest of the explanation more than they should.

What he got right: bloodwork-guided cycling is better than calendar-based cycling. That is defensible. The point that a 200mg weekly testosterone dose carries health risks that users should acknowledge is also honest. And the observation that cold-turkey cessation after prolonged AAS use can tank endogenous hormone production is consistent with what endocrinologists report in post-cycle hypogonadism cases.

• Accurate: bloodwork should guide cycling decisions, not fixed time windows
• Accurate: prolonged AAS use suppresses endogenous testosterone production
• Inaccurate: SERMs cause DVT via arterial lacerations
• Misleading: framing all SERMs as uniformly "inherently toxic" without distinguishing risk profiles

What should you actually know?

If you are using anabolic steroids outside a supervised medical context, no TikTok video replaces a physician. That is not a disclaimer for decoration. The cardiovascular data on long-term supraphysiologic testosterone use is sobering: Baggish et al. found that 52% of long-term AAS users had impaired diastolic function versus 17% of non-users. These are not rare edge cases.

On SERMs specifically: tamoxifen and raloxifene do carry thrombotic risk, but they are also used clinically for gynecomastia and post-cycle hormone recovery under physician supervision. The risk is real and worth knowing. The mechanism is not arterial cuts. If a SERM is prescribed by a licensed provider for a legitimate reason, the VTE risk is weighed against the benefit in that specific clinical context, not dismissed wholesale.

The 200mg per week ceiling the creator mentions is also not a medically established safe threshold. Legitimate TRT doses in hypogonadal men typically target physiologic serum testosterone levels, which usually requires 100-200mg per week depending on the individual and the ester used. Using 200mg specifically to maintain a supraphysiologic baseline between blasts is a different clinical situation entirely and should not be framed as a health-maintaining dose without that context.